资讯

该研究的临床价值在于建立Dupilumab治疗AD的标准化眼表监测方案:对于基线眼睑湿疹患者建议预防性人工泪液治疗;出现角膜缘炎症等重症表现时及时转诊眼科;开发局部钙调磷酸酶抑制剂等新型治疗策略。
这项研究首次系统报道了dupilumab在免疫缺陷-移植-罕见病三重难题中的卓越表现,为特殊人群的精准治疗打开了新思路。 研究采用标准化的疗效评估体系,包括湿疹面积和严重程度指数(Eczema Area and Severity Index, EASI)和儿童皮肤病生活质量指数(Children's Dermatology Life Quality Index, CDLQI)。
2023年11月17日,制药公司赛诺菲(Sanofi)宣布, Dupilumab(通用名:度普利尤单抗)在中国获批用于12岁及以上青少年和成人哮喘患者的维持治疗。 度 ...
Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.
Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.
Dupilumab(度普利尤单抗),一种结合IL-4Rα并抑制IL-4和IL-13信号传导的全人源单克隆抗体,一经获批上市即在特应性皮炎和哮喘等疾病领域“大展身手 ...
日前,Regeneron Pharmaceuticals和赛诺菲(Sanofi)公司宣布,两公司联合开发的重磅药物Dupixent(dupilumab),在治疗鼻息肉慢性鼻窦炎(CRSwNP)成人患者的 ...
Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.
With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...
Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...
Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively increasing symptom burden, exercise limitations, and frequent ...